et al., International Journal of Nanomedicine, doi:10.2147/IJN.S313093 (Peer Reviewed)
RCT 114 patients in Egypt, 57 treated with ivermectin mucoadhesive nanosuspension intranasal spray, showing faster recovery and viral clearance with treatment. NCT04716569.
Aref et al., 6/15/2021, Randomized Controlled Trial, Egypt, Middle East, peer-reviewed, 7 authors.
relative duration of fever, 63.2% lower, relative time 0.37, p < 0.001, treatment 57, control 57.
risk of no virological cure, 78.6% lower, RR 0.21, p = 0.004, treatment 3 of 57 (5.3%), control 14 of 57 (24.6%).
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.